HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Angiomyolipoma — Clinical Guidelines

Overview

Angiomyolipomas (AMLs) are benign mesenchymal tumors most commonly found in the kidney, often associated with tuberous sclerosis. They are typically asymptomatic but can present with complications such as hemorrhage or rupture 1 2.

Diagnosis

Imaging Characteristics: CT and MRI are crucial; presence of fat is key for diagnosis 2.

Fat Identification: Essential for distinguishing AML from other renal masses 2.

Histopathology: Confirms diagnosis, showing characteristic smooth muscle, fat, and blood vessel components 3.

Extrarenal AMLs: Rare but can occur; diagnosis similar but context important 7.

Management

Observation: Majority can be monitored without intervention if asymptomatic 2.

Embolization: First-line for preventing or managing hemorrhage; subselective particle embolization preferred 2.

Surgical Intervention: Reserved for cases with rupture, large size, or suspected malignancy 1 2.

Nephrectomy: Considered in malignant transformation or extensive involvement 3.

Special Populations

Tuberous Sclerosis: AMLs more frequent; careful monitoring advised 2 3.

Extrarenal AMLs: Treated surgically with simple excision; no reported cases with tuberous sclerosis 7.

Key Recommendations

Monitor asymptomatic AMLs without intervention unless risk factors for complications are present (Evidence: Moderate 2).

Use subselective particle embolization for managing or preventing hemorrhage in symptomatic or high-risk AMLs (Evidence: Moderate 2).

Consider surgical options such as nephrectomy for malignant transformation or extensive intrarenal extension (Evidence: Weak 3).

References

1 Haim D, Bachar G. [SPONTANEOUS RUPTURE OF A RENAL ANGIOMYOLIPOMA]. Harefuah 2025. link 2 Halpenny D, Snow A, McNeill G, Torreggiani WC. The radiological diagnosis and treatment of renal angiomyolipoma-current status. Clinical radiology 2010. link 3 Moudouni SM, Tligui M, Sibony M, Doublet JD, Haab F, Gattegno B et al.. Malignant epithelioid renal angiomyolipoma involving the inferior vena cava in a patient with tuberous sclerosis. Urologia internationalis 2008. link 4 Naik R, Kamath AS. Angiomyolipoma of kidney: a case report. Indian journal of pathology & microbiology 1993. link 5 Mehregan DA, Mehregan DR, Mehregan AH. Angiomyolipoma. Journal of the American Academy of Dermatology 1992. link70193-j) 6 Moros García M, Martinez Tello D, Ramon y Cajal Junquera S, Valdivia Uria G, Romero Aguirre F, Ortego Fernandez de Retana J. Multiple cavernous hemangioma of the kidney. European urology 1988. link 7 Randazzo RF, Neustein P, Koyle MA. Spontaneous perinephric hemorrhage from extrarenal angiomyolipoma. Urology 1987. link90517-6) 8 Yum M, Ganguly A, Donohue JP. Juxtaglomerular cells in renal angiomyolipoma. Ultrastructural observation. Urology 1984. link90362-5) 9 Perry NM, Webb JA, White FE, Whitfield HN. Hemorrhagic angiomyolipoma of the kidney. The Journal of urology 1984. link49856-9)

Angiomyolipoma